C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background Metabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, therefore, aimed to define the relationship between insulin C-peptide as a marker of β-cell function and metabolic outcomes in new-onset type 1 diabetes. Methods 21 trials of disease-modifying interventions within 100 days of type 1 diabetes diagnosis comprising 1315 adults (ie, those 18 years and older) and 1396 children (ie, those younger than 18 years) were combined. Endpoints assessed were stimulated area under the curve C-peptide, HbA 1c , insulin use, hypoglycaemic events, and composite scores (such as insulin dose adjusted A 1c , total daily insulin, U/kg per day, and BETA-2 score). Positive studies were defined as those meeting their primary endpoint. Differences in outcomes between active and control groups were assessed using the Wilcoxon rank test. Findings 6 months after treatment, a 24·8% greater C-peptide preservation in positive studies was associated with a 0·55% lower HbA 1c (p<0·0001), with differences being detectable as early as 3 months. Cross-sectional analysis, combining positive and negative studies, was consistent with this proportionality: a 55% improvement in C-peptide preservation was associated with 0·64% lower HbA 1c (p<0·0001). Higher initial C-peptide levels and greater preservation were associated with greater improvement in HbA 1c . For HbA 1c , IDAAC, and BETA-2 score, sample size predictions indicated that 2–3 times as many participants per group would be required to show a difference at 6 months as compared with C-peptide. Detecting a reduction in hypoglycaemia was affected by reporting methods. Interpretation Interventions that preserve β-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA 1c are directly proportional to the degree of C-peptide preservation, quantifying this relationship, and supporting the use of C-peptides as a surrogate endpoint in clinical trials. Funding JDRF and Diabetes UK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citationRituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationRawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802
Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010
Livingstone, S. J., Levin, D., Looker, H. C., Lindsay, R. S., Wild, S. H., Joss, N., Leese, G., Leslie, P., McCrimmon, R. J., Metcalfe, W., et al. (2015) · JAMA · doi:10.1001/jama.2014.16425 · Cited by 621
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Self-citationInternational Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608 · cited 1×
“39 As continuous glucose monitoring data were only available in 265 participants, continuous-glucose-monitoring-detected hypoglycaemia was not included in this analysis.”
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493 · cited 5×
“This finding was mainly driven by the largest negative study (Protégé), 18 which recruited a large number of participants from the Indian sub-continent who had lower C-peptide concentrations, higher insulin use, and higher HbA 1c than those recruited from North America and Europe.”
BackgroundResultInfluentialSelf-citationPalmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationWherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Self-citationTeplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes · doi:10.2337/db13-0236 · Cited by 247 · cited 1×
“Prospective studies in new-onset type 1 diabetes not meeting clinical endpoints 11,18,22 despite preserving C-peptide has raised concerns among drug developers and has challenged the role of C-peptide as a surrogate endpoint.”
BackgroundSelf-citation
Cited by
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
“A growing number of studies continue to focus on Stage 3, where a recent meta-analysis demonstrated a link be-tween maintenance of residual C-peptide and clinical outcomes such as reductions in HbA1c and insulin doses [123].”
Self-citationLatres, E., Greenbaum, C. J., Oyaski, M. L., Dayan, C. M., Colhoun, H. M., Lachin, J. M., Skyler, J. S., Rickels, M. R., Ahmed, S. T., Dutta, S., et al. (2024) · Diabetes · doi:10.2337/dbi23-0012 · Cited by 35
Self-citationA Golden Hour and Golden Opportunity for β-Cell Preservation
Evans-Molina, C., & Oram, R. A. (2024) · Diabetes · doi:10.2337/dbi24-0019 · Cited by 10
Metadata
- Authors
- Taylor, P. N., Collins, K. S., Lam, A., Karpen, S. R., Greeno, B., Walker, F., Lozano, A., Atabakhsh, E., Ahmed, S. T., Marinac, M., Latres, E., Senior, P. A., Rigby, M., Gottlieb, P. A., Dayan, C. M., Greenbaum, C., Krisher, J., Skyler, J., Wherrett, D., Hannelius, U., Lindqvist, A., Nowak, C., Bebu, I., Braffett, B., Napolitano, A., Jan Mohamed, S., Weir, G., Nepom, G., Beck, R., Richard, C., Hedrick, J., Ludvigsson, J., Von Herrath, M., Leon, F., Ramos, E., Narendran, P., Gitelman, S., Dabelea, D., Andrews, R., Haller, M., Jensen, E., Harold, K., & Dutz, J.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-12
- Volume
- 11
- Issue
- 12
- Pages
- 915-925
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4388278575
- Cited by
- 62
- References
- 15
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. https://app.cochat.ai/papers/10.1016/s2213-8587(23)00267-x
- The paper
- Taylor, P. N., Collins, K. S., Lam, A., Karpen, S. R., Greeno, B., Walker, F., Lozano, A., Atabakhsh, E., Ahmed, S. T., Marinac, M., Latres, E., Senior, P. A., Rigby, M., Gottlieb, P. A., Dayan, C. M., Greenbaum, C., Krisher, J., Skyler, J., Wherrett, D., . . . Dutz, J. (2023). C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00267-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.